Atlas Trials

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

Clinical trial NCT05481411 · COMPLETED

Trial details

NCT number
NCT05481411
Sponsor
Amgen
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatic Impairment
Start date
2022-09-13
Primary completion
2023-04-05
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.